iShares US Power Infrastructure ETF vs Regeneron Pharmaceuticals Inc — how do they compare? iShares US Power Infrastructure ETF trades at $25.71, while Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.46% dividend while iShares US Power Infrastructure ETF pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, iShares US Power Infrastructure ETF nearer its low. Which is the better fit depends on your goals.
| POWR | REGN | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $28.22 | $852.03 |
52-Week Low | $23.20 | $555.51 |
Market Cap | — | $83.43B |
Enterprise Value | — | $78.14B |
Dividend Yield | — | 0.46% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
Trailing returns across standard periods
Latest headlines on both assets
iShares U.S. Power Infrastructure ETF seeks exposure to U.S. companies involved in power infrastructure. Its holdings may include electric utilities, transmission and distribution businesses, and electrical equipment providers.
Read more on POWR →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →